Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure.

Frolik CA, Black EC, Cain RL, Satterwhite JH, Brown-Augsburger PL, Sato M, Hock JM

Bone1 Sept 2003Cited by 154 (Europe PMC)

PMID13678779DOI10.1016/s8756-3282(03)00202-3PepBankPUB-13678779

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In young male rats, six PTH injections over 6 h decreased tibia bone mass.
In plain wordsIn rats, six PTH injections over 6 h decreased tibia bone mass.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTibia bone mass
Study
ratn: not reported in source
Young male rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 microg/kg/day, six injections over six hoursAs given in this study (rat).
Source sentences
Summary
In contrast, 6 PTH(1-34) injections/day over 6 h for a total dose of 80 microg/kg/day or 3 injections/day over 8 h for a total of 240 microg/kg/day decreased tibia bone mass.
1 context sentence(design, population, supporting numbers)
Summary · context
To determine the pharmacokinetic profile of PTH(1-34) associated with anabolic and catabolic bone responses, PTH(1-34) pharmacokinetic and serum biochemical profiles were evaluated in young male rats using dosing regimens that resulted in either gain or loss of bone mass.
Report a problemFND-1367877902
02AnimalAnimal study (in vivo)Efficacy outcome
In young male rats, three PTH injections over 8 h decreased tibia bone mass.
In plain wordsIn rats, three PTH injections over 8 h decreased tibia bone mass.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTibia bone mass
Study
ratn: not reported in source
Young male rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
240 microg/kg/day, three injections over eight hoursAs given in this study (rat).
Source sentences
Summary
In contrast, 6 PTH(1-34) injections/day over 6 h for a total dose of 80 microg/kg/day or 3 injections/day over 8 h for a total of 240 microg/kg/day decreased tibia bone mass.
1 context sentence(design, population, supporting numbers)
Summary · context
To determine the pharmacokinetic profile of PTH(1-34) associated with anabolic and catabolic bone responses, PTH(1-34) pharmacokinetic and serum biochemical profiles were evaluated in young male rats using dosing regimens that resulted in either gain or loss of bone mass.
Report a problemFND-1367877903
03AnimalAnimal study (in vivo)Pharmacokinetics
In rats, the catabolic PTH regimen maintained serum PTH above baseline throughout the dosing period.
In plain wordsIn rats, the regimen associated with bone loss kept blood PTH above baseline throughout dosing.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSustained PTH concentrations
Study
ratn: not reported in source
Young male rats
Comparator
Baseline
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
the catabolic regimen was associated with PTH(1-34) concentrations remaining above baseline values during the entire 6-h dosing period
1 context sentence(design, population, supporting numbers)
Summary · context
To determine the pharmacokinetic profile of PTH(1-34) associated with anabolic and catabolic bone responses, PTH(1-34) pharmacokinetic and serum biochemical profiles were evaluated in young male rats using dosing regimens that resulted in either gain or loss of bone mass.
Report a problemFND-1367877906
04AnimalAnimal study (in vivo)Efficacy outcome
In rats, the anabolic PTH profile included a rapid decrease in serum calcium.
In plain wordsIn rats, blood calcium decreased rapidly with the PTH profile associated with bone gain.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum calcium with anabolic regimen
Study
ratn: not reported in source
Young male rats
Outcome group
Bone and joint · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Compared to the anabolic pharmacokinetic profile of a transient increase in PTH(1-34) with rapid decreases in serum calcium and phosphate
1 context sentence(design, population, supporting numbers)
Summary · context
To determine the pharmacokinetic profile of PTH(1-34) associated with anabolic and catabolic bone responses, PTH(1-34) pharmacokinetic and serum biochemical profiles were evaluated in young male rats using dosing regimens that resulted in either gain or loss of bone mass.
Report a problemFND-1367877907
05AnimalAnimal study (in vivo)Efficacy outcome
In rats, the anabolic PTH profile included a rapid decrease in serum phosphate.
In plain wordsIn rats, blood phosphate decreased rapidly with the PTH profile associated with bone gain.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum phosphate with anabolic regimen
Study
ratn: not reported in source
Young male rats
Outcome group
Bone and joint · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Compared to the anabolic pharmacokinetic profile of a transient increase in PTH(1-34) with rapid decreases in serum calcium and phosphate
1 context sentence(design, population, supporting numbers)
Summary · context
To determine the pharmacokinetic profile of PTH(1-34) associated with anabolic and catabolic bone responses, PTH(1-34) pharmacokinetic and serum biochemical profiles were evaluated in young male rats using dosing regimens that resulted in either gain or loss of bone mass.
Report a problemFND-1367877908
06AnimalAnimal study (in vivo)Efficacy outcome
In rats, the catabolic PTH regimen showed a trend toward increased serum calcium.
In plain wordsIn rats, blood calcium tended to increase with the PTH regimen associated with bone loss.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum calcium with catabolic regimen
Study
ratn: not reported in source
Young male rats
Outcome group
Bone and joint · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
the catabolic regimen was associated with PTH(1-34) concentrations remaining above baseline values during the entire 6-h dosing period with a trend toward an increase in serum calcium and a prolonged decrease in phosphate.
1 context sentence(design, population, supporting numbers)
Summary · context
To determine the pharmacokinetic profile of PTH(1-34) associated with anabolic and catabolic bone responses, PTH(1-34) pharmacokinetic and serum biochemical profiles were evaluated in young male rats using dosing regimens that resulted in either gain or loss of bone mass.
Report a problemFND-1367877909
07AnimalAnimal study (in vivo)Efficacy outcome
In rats, the catabolic PTH regimen showed a prolonged decrease in serum phosphate.
In plain wordsIn rats, blood phosphate decreased for a prolonged period with the PTH regimen associated with bone loss.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum phosphate with catabolic regimen
Study
ratn: not reported in source
Young male rats
Outcome group
Bone and joint · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
the catabolic regimen was associated with PTH(1-34) concentrations remaining above baseline values during the entire 6-h dosing period with a trend toward an increase in serum calcium and a prolonged decrease in phosphate.
1 context sentence(design, population, supporting numbers)
Summary · context
To determine the pharmacokinetic profile of PTH(1-34) associated with anabolic and catabolic bone responses, PTH(1-34) pharmacokinetic and serum biochemical profiles were evaluated in young male rats using dosing regimens that resulted in either gain or loss of bone mass.
Report a problemFND-1367877910

Studies that did not test the peptide alone3

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

08AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In young male rats, once-daily PTH and six injections within one hour induced equivalent proximal tibia bone mass increases.
In plain wordsIn rats, once-daily PTH and six injections within one hour produced similar tibia bone mass increases.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseProximal tibia bone mass
Study
ratn: not reported in source
Young male rats
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Once-daily PTH(1-34) or 6 PTH(1-34) injections within 1 h, for a total daily dose of 80 microg/kg, induced equivalent increases in proximal tibia bone mass.
1 context sentence(design, population, supporting numbers)
Summary · context
To determine the pharmacokinetic profile of PTH(1-34) associated with anabolic and catabolic bone responses, PTH(1-34) pharmacokinetic and serum biochemical profiles were evaluated in young male rats using dosing regimens that resulted in either gain or loss of bone mass.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1367877901
09AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Pharmacokinetics
In rats, the maximum serum PTH concentration did not predict the catabolic bone outcome.
In plain wordsIn rats, peak blood PTH levels did not predict bone loss.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableCmax prediction of bone loss
Study
ratn: not reported in source
Young male rats
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The magnitude of the maximum serum concentrations (Cmax) of PTH(1-34) and area under the curve (AUC) did not predict the catabolic bone outcome.
1 context sentence(design, population, supporting numbers)
Summary · context
To determine the pharmacokinetic profile of PTH(1-34) associated with anabolic and catabolic bone responses, PTH(1-34) pharmacokinetic and serum biochemical profiles were evaluated in young male rats using dosing regimens that resulted in either gain or loss of bone mass.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1367877904
10AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Pharmacokinetics
In rats, PTH exposure measured by area under the curve did not predict the catabolic bone outcome.
In plain wordsIn rats, total blood PTH exposure did not predict bone loss.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableAUC prediction of bone loss
Study
ratn: not reported in source
Young male rats
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The magnitude of the maximum serum concentrations (Cmax) of PTH(1-34) and area under the curve (AUC) did not predict the catabolic bone outcome.
1 context sentence(design, population, supporting numbers)
Summary · context
To determine the pharmacokinetic profile of PTH(1-34) associated with anabolic and catabolic bone responses, PTH(1-34) pharmacokinetic and serum biochemical profiles were evaluated in young male rats using dosing regimens that resulted in either gain or loss of bone mass.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1367877905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.